Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 12, 2012 - Issue 3
Submit an article Journal homepage
46
Views
9
CrossRef citations to date
0
Altmetric
Research Report

Initiatives to improve prescribing efficiency for drugs to treat Parkinson’s disease in Croatia: influence and future directions

Ljiljana Sovic Brkicic Croatian Institute for Health Insurance, Margaretska 3, Zagreb, Croatia
,
Brian Godman Division of Clinical Pharmacology, Karolinska Institute, Huddinge, SE-141 86 Stockholm, Sweden. [email protected]; Mario Negri Institute for Pharmacological Research, Milan, Italy; Division of Clinical Pharmacology, Karolinska Institute, Huddinge, SE-141 86 Stockholm, Sweden. [email protected]; Mario Negri Institute for Pharmacological Research, Milan, Italy
,
Luka Voncina Ministry of Health, Republic of Croatia, Ksaver 200a, Zagreb, Croatia
,
Slavica Sovic School of Medicine, Andrija Stampar School of Public Health, University of Zagreb, Zagreb, Croatia
&
Maja Relja Department of Neurology, School of Medicine, Clinical Medical Centre Zagreb, University of Zagreb, Zagreb, Croatia
Pages 373-384 | Published online: 09 Jan 2014

References

  • Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl. Health Econ. Health Policy 8(1), 7–24 (2010).
  • Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 26(7), 537–550 (2008).
  • Godman B, Shrank W, Wettermark B et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470–2494 (2010).
  • Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9(6), 569–581 (2009).
  • Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10(6), 707–722 (2010).
  • Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res. 8(4), 357–371 (2008).
  • Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Frontiers Pharmacol. 1(141), 1–16 (2011).
  • Voncina L, Strizrep T, Godman B et al. Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe; implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11(4), 469–479 (2011).
  • Garattini S, Bertele’ V, Godman B, Haycox A, Wettermark B, Gustafsson LL; Piperska Group. Enhancing the rational use of new medicines across European health care systems. Eur. J. Clin. Pharmacol. 64(12), 1137–1138 (2008).
  • Godman B, Wettermark B, Bishop I et al. European payer initiatives to reduce prescribing costs through use of generics. GaBI 1, 22–27 (2012).
  • Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res. 12(1), 125–130 (2012).
  • Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 9(5), 475–484 (2009).
  • Voncina L, Strizrep T. Croatia: 2009/2010 pharmaceutical pricing and reimbursement reform. Eurohealth 16, 20–22 (2011).
  • Voncina L, Strizrep T, Godman B, Vlahovic-Palcevski V. Recent policies to enhance prescribing efficiency in Croatia: their impact and future guidance. Pharmacoepidemiol. Drug Saf. 20, S209 (2011).
  • Voncina L, Strizrep T, Bagat M, Pezelj-Duliba D, Pavic N. Croatian 2008–2010 health insurance reform: hard choices toward financial sustainability and efficiency. Croat. Med. J. 53(1), 66–76 (2012).
  • Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp FM. Soft regulations in pharmaceutical policy making: an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7(3), 137–147 (2009).
  • Godman B, Malmström RE, Bennie M et al. Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency? Rev. Health Care 3, 5–16 (2012).
  • Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91–98 (2008).
  • Oertel WH, Quinn NP. Parkinsonism. In: Neurological Disorders: Course and Treatment. Brandt T, Diener HC, Caplan LR (Eds). Academic Press, CA, USA, 715–772 (2003).
  • Spottke AE, Reuter M, Machat O et al. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics 23(8), 817–836 (2005).
  • Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1(8007), 345–349 (1977).
  • Lindgren P. Economic evidence in Parkinson’s disease: a review. Eur. J. Health Econ. 5(Suppl. 1) 63–66 (2004).
  • Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342(20), 1484–1491 (2000).
  • Trifirò G, Savica R, Morgante L et al. Prescribing pattern of anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003–2005. Parkinsonism Relat. Disord. 14(5), 420–425 (2008).
  • Oertel WH, Quinn NP. Parkinson’s disease: drug therapy. Baillieres Clin. Neurol. 6(1), 89–108 (1997).
  • Askmark H, Antonov K, Aquilonius SM. The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption – a nation-wide perspective in Sweden. Parkinsonism Relat. Disord. 9(5), 271–276 (2003).
  • Münchau A, Bhatia KP. Pharmacological treatment of Parkinson’s disease. Postgrad. Med. J. 76(900), 602–610 (2000).
  • Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 68(6), 685–689 (2000).
  • Lees A. Alternatives to levodopa in the initial treatment of early Parkinson’s disease. Drugs Aging 22(9), 731–740 (2005).
  • Magyar K. The pharmacology of selegiline. Int. Rev. Neurobiol. 100, 65–84 (2011).
  • Yasar S, Bergman J. Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies. Clin. Pharmacol. Ther. 56(6 Pt 2), 768–773 (1994).
  • Parashos SA, Swearingen CJ, Biglan KM et al.; NET-PD Investigators. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch. Neurol. 66(9), 1099–1104 (2009).
  • Clarke CE. Parkinson’s disease. BMJ 335(7617), 441–445 (2007).
  • Leoni O, Martignoni E, Cosentino M et al. Drug prescribing patterns in Parkinson’s disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol. Drug Saf. 11(2), 149–157 (2002).
  • Menniti-Ippolito F, Spila-Alegiani S, Vanacore N et al. Estimate of parkinsonism prevalence through drug prescription histories in the province of Rome, Italy. Acta Neurol. Scand. 92(1), 49–54 (1995).
  • Lai BC, Schulzer M, Marion S, Teschke K, Tsui JK. The prevalence of Parkinson’s disease in British Columbia, Canada, estimated by using drug tracer methodology. Parkinsonism Relat. Disord. 9(4), 233–238 (2003).
  • Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63(9), 1320–1326 (2009).
  • Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – are drug utilisation data comparable? Eur. J. Clin. Pharmacol. 56(9-10), 723–727 (2000).
  • Vlahovic-Palcevski V, Gantumur M, Radosevic N, Palcevski G, Vander Stichele R. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm. World Sci. 32(2), 125–129 (2010).
  • Vlaar A, Hovestadt A, van Laar T, Bloem BR. The treatment of early Parkinson’s disease: levodopa rehabilitated. Pract. Neurol. 11(3), 145–152 (2011).
  • Zapia M, Colosimo C, Levodopa PW. Back to the future. J. Neurol. 257(Suppl. 2) 247–248 (2010).
  • Hornykiewicz O. A brief history of levodopa. J. Neurol. 257(Suppl. 2), 249–252 (2010).
  • Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs 21(8), 677–692 (2007).
  • Waldvogel D. [Medical treatment of Parkinson’s disease]. Ther. Umsch. 64(1), 15–20 (2007).
  • Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson’s disease: a meta analysis. Int. J. Clin. Pract. 63(4), 613–623 (2009).
  • Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacol. Rep. 57(6), 701–712 (2005).
  • Kondo T. Initial therapy for Parkinson’s disease: levodopa vs. dopamine receptor agonists. J. Neurol. 249(Suppl. 2), II25–II29 (2002).
  • Clarke CE, Speller JM, Clarke JA. Pramipexole versus bromocriptine for levodopa-induced complications in parkinson’s disease. Cochrane Database Syst. Rev. 3, CD002259 (2000).
  • Clarke CE, Deane KH. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst. Rev. 1, CD001517 (2001).
  • Earley CJ. Clinical practice. Restless legs syndrome. N. Engl. J. Med. 348(21), 2103–2109 (2003).
  • Gazette of the Croatian Government. Ordinance establishing the criteria for wholesale pricing of medical products and the method for reporting wholesale prices. National Gazette, 28th December (2009).
  • Gazette of the Croatian Government. Ordinance for the criteria establishing National Drug Reimbursement List and Supplementary Drug List. National Gazette, 28th December (2009).
  • Gazette of the Croatian Government. Ordinance amending the corrections of Ordinance establishing the criteria for wholesale pricing of medical products and the method for reporting wholesale prices. National Gazette, 17th February (2010).
  • Gazette of the Croatian Government. Decision of establishing Particularly Expensive Drug List based on Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 10th February (2010).
  • Gazette of the Croatian Government. Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 7th June (2010).
  • Gazette of the Croatian Government. Decision of establishing Supplementary Drug List of the Croatian Institute for Health Insurance. National Gazette, 7th June (2010).
  • Gazette of the Croatian Government. Decision of establishing Particularly Expensive Drug List based on decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 7th June (2010).
  • Gazette of the Croatian Government. Correction of Decision of establishing Particularly Expensive Drug List based on Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 19th June (2010).
  • Gazette of the Croatian Government. Correction of Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 5th July (2010).
  • Gazette of the Croatian Government. Correction of Decision of establishing Supplementary Drug List of the Croatian Institute for Health Insurance. National Gazette, 5th July (2010).
  • Gazette of the Croatian Government. Decision of correction of Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 24th November (2010).
  • Gazette of the Croatian Government. Decision of correction of Decision of establishing Supplementary Drug List of the Croatian Institute for Health Insurance. National Gazette, 24th November (2010).
  • Gazette of the Croatian Government. Decision of establishing Particularly Expensive Drug List based on Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 24th November (2010).
  • Gazette of the Croatian Government. Decision of correction of Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 3rd January (2011).
  • Gazette of the Croatian Government. Decision of correction of Decision of establishing Supplementary Drug List of the Croatian Institute for Health Insurance. National Gazette, 3rd January (2011).
  • Gazette of the Croatian Government. Decision of corrections of Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 13th May (2011).
  • Gazette of the Croatian Government. Decision of corrections of Decision of establishing Supplementary Drug List of the Croatian Institute for Health Insurance. National Gazette, 13th May (2011).
  • Gazette of the Croatian Government. Decision of corrections of Decision of establishing Particularly Expensive Drug List based on Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 13th May (2011).
  • Gazette of the Croatian Government. Decision of corrections of Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 3rd June (2011).
  • Gazette of the Croatian Government. Decision of corrections of Decision of establishing Particularly Expensive Drug List based on Decision of establishing National Drug Reimbursement List of the Croatian Institute for Health Insurance. National Gazette, 10th August (2011).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.